Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press23010.17650/1994-4098-2010-0-2-47-52MAMMOLOGY. PHARMACOTHERAPYМАММОЛОГИЯ. ФАРМАКОТЕРАПИЯEfficacy of Heptral® in the treatment of hepatic toxicity induced by cytostatic chemotherapyЭффективность Гептрала® в лечении печеночной токсичности, обусловленной цитостатической химиотерапиейSnegovoyA. V.СнеговойА. В.
Russian Federation
a_snegovoi@list.ruManzyukL. V.МанзюкЛ. В.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowГУ РОНЦ им.Н.Н. Блохина РАМН, Москва270520102475227082014270820142010https://ojrs.abvpress.ru/ojrs/article/view/230

The efficacy of Heptral® (ademethionine) was evaluated in the treatment of chemotherapy-induced hepatotoxicity in 19 patients with various malignancies. Four-week administration of oral Heptral® 400 mg twice daily was shown to reduce the level of transaminases to normal values in 10 of 12 patients with grade 1 toxicity. Longer (2-to-4 month) use of Heptral® was required to normalize the level of transminases in grade 2 hepatotoxicity. The chemotherapy regimen was not changed during the use of this drug.

У 19 пациентов с различными злокачественными опухолями проведена оценка эффективности препарата Гептрал® (адеметионин) при лечении гепатотоксичности, индуцированной химиотерапией. Показано, что при 4-недельном приеме Гептрала® внутрь по 400 мг 2 раза в день уровень трансаминаз снизился до нормы у 10 из 12 пациентов с I степенью гепатотоксичности. Для нормализации уровня трансаминаз при II степени гепатотоксичности потребовался более длительный прием Гептрала® (от 2 до 4 мес). Режим химиотерапии в период применения Гептрала® не менялся.

chemotherapyhepatotoxicitytransaminaseademethionineхимиотерапиягепатотоксичностьтрансаминазаадеметионин1. King P.D., Perry M.C. Hepatoioxiciry of chemotherapy. The Oncologist 2001;6:162–76.King P.D., Perry M.C. Hepatoioxiciry of chemotherapy. The Oncologist 2001;6:162–76.2. DeLeve L.D., Kaplovitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:787–810.DeLeve L.D., Kaplovitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:787–810.3. Dansette P.M., Bonierbale E., Minoletti С. et al. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998;23: 443–51.Dansette P.M., Bonierbale E., Minoletti С. et al. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998;23: 443–51.4. Kaplowitz N., Aw T.Y., Simon F.R., Stolz A. Drug-induced hepatotoxicity. Ann Intern Med 1986; 104: 826–39.Kaplowitz N., Aw T.Y., Simon F.R., Stolz A. Drug-induced hepatotoxicity. Ann Intern Med 1986; 104: 826–39.5. Ishak K.G., Zimmerman H.J. Morphologic spectrums of drug-induced liver disease. Gastroenterol Clin North Am 1995;24: 759–86.Ishak K.G., Zimmerman H.J. Morphologic spectrums of drug-induced liver disease. Gastroenterol Clin North Am 1995;24: 759–86.6. Larrey D. Drug-induced liver diseases. J Hepatol 2000;32: 77–88.Larrey D. Drug-induced liver diseases. J Hepatol 2000;32: 77–88.7. Zorti D. et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. British Journal of Surgery 2007; 94: 274–86.Zorti D. et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. British Journal of Surgery 2007; 94: 274–86.8. Paul D.King et al. Hepatotoxicity of chemotherapy. The Oncologist 2001;6:162–76.Paul D.King et al. Hepatotoxicity of chemotherapy. The Oncologist 2001;6:162–76.9. O' Grady J.G. Paracetamol-induced acute liver failure: prevention and management. J Hepatol 1997;26: 41–6.O' Grady J.G. Paracetamol-induced acute liver failure: prevention and management. J Hepatol 1997;26: 41–6.10. Strieker B.H. Drug-induced Hepatic Injury. 2nd edn. Amsterdam: Elsevier, 1992.Strieker B.H. Drug-induced Hepatic Injury. 2nd edn. Amsterdam: Elsevier, 1992.11. Pessayre D., Larrey D., Biour M. Drug-induced liver injury. In: Bircher J., Benhamou J.P., Mcintire N., Rizzetto M., Rodes J., editors. Oxford Textbook of Clinical Hepatology, 2nd edn, Vol 2, 1999, Oxford University Press, p. 1261–315.Pessayre D., Larrey D., Biour M. Drug-induced liver injury. In: Bircher J., Benhamou J.P., Mcintire N., Rizzetto M., Rodes J., editors. Oxford Textbook of Clinical Hepatology, 2nd edn, Vol 2, 1999, Oxford University Press, p. 1261–315.12. Hirata F., Viveros O.H., Diliberto E.J.Jr., Axelrod J. Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine. Proc Natl Acad Sci USA 1978;75: 1718–21.Hirata F., Viveros O.H., Diliberto E.J.Jr., Axelrod J. Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine. Proc Natl Acad Sci USA 1978;75: 1718–21.13. Kretzschmar M., Klinger W. The hepatic glutathione system influences of xenobiotics. Exp Pathol 1990;38:145–64.Kretzschmar M., Klinger W. The hepatic glutathione system influences of xenobiotics. Exp Pathol 1990;38:145–64.14. Cabrero C., Duce A.M., Ortiz P. et al. Specific loss of the high-molecular- weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology 1988; 8:1530–4.Cabrero C., Duce A.M., Ortiz P. et al. Specific loss of the high-molecular- weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology 1988; 8:1530–4.15. Cantoni G.L. The nature of the active methyl donor formed enzymically from L-methionine and adenosine triphosphate. J Am Chem Soc 1952;74: 2942–3.Cantoni G.L. The nature of the active methyl donor formed enzymically from L-methionine and adenosine triphosphate. J Am Chem Soc 1952;74: 2942–3.16. Dunne J.B., Davenport M., Williams R., Tredger J.M. Evidence that S-adenosylmethionine andDunne J.B., Davenport M., Williams R., Tredger J.M. Evidence that S-adenosylmethionine andN-acetylcysteine reduce injury from sequential cold and warm ischaemia in the isolated perfused rat liver. Transplantation 1994; 57: 1161–8.17. Mato J.M., Camara J., Fernandez de Paz J. et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081–9.Mato J.M., Camara J., Fernandez de Paz J. et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081–9.18. Giudici G.A., Le Grazie С., Di Padova C. The use of ademethionine (SAMe) in the treatmen of cholestaticGiudici G.A., Le Grazie С., Di Padova C. The use of ademethionine (SAMe) in the treatmen of cholestaticliver disorders: meta-analvsis of clinical trials. In: Мato JM, Lieber C, Kaplowitz N, Caballero A, editors. Methionine Metabolism: Molecular Mechanism and Clinical Implications. Madrid: CSIC Press, 1992; p. 67–9.19. Feliu J., Mel J.R.. Camps C. et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. An active and low toxicity regimen. Eur J Cancer 2002;З8; 1204–11.Feliu J., Mel J.R.. Camps C. et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. An active and low toxicity regimen. Eur J Cancer 2002;З8; 1204–11.20. Cascinu S., Graziano F., Ferrau F. et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002;13: 716–20.Cascinu S., Graziano F., Ferrau F. et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002;13: 716–20.